Drugs / Finasteride
Finasteride
also known as
Proscar · Propecia · Aindeem · CU-40102 · FIN · Finasterida · Finasteride component of entadfi · IY001 · +5 more
Small molecule targets SRD5A2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed androgenetic alopecia 3 milestones | |||||
| Filed | China (NMPA) | — | androgenetic alopecia | 2025-11-18 | “Abbreviated New Drug Application (ANDA) for CU-40105 (self-developed topical finasteride spray) has been accepted by the NMPA.” cutiatx.com ↗ |
| Filed | Other | — | androgenetic alopecia | 2024-04-29 | “for CU-40102 (topical finasteride spray) of the Group was submitted to the Department of Health” cutiatx.com ↗ |
| Filed | China (NMPA) | — | androgenetic alopecia | 2024-01-30 | “for CU-40102 (topical finasteride spray) was accepted by the National Medical Products Administration (the “NMPA”) of the PRC” cutiatx.com ↗ |
| Filed benign prostatic hyperplasia 1 milestone | |||||
| Filed | US (FDA) | TADFIN | benign prostatic hyperplasia | 2021-02-23 | “An NDA was submitted in February 2021 for TADFIN ™ (tadalafil 5mg and finasteride 5mg) capsule” verupharma.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (2) | US (FDA) | PROSCAR | — | 1998-03-20 – 2004-04-12 | fda.gov ↗ |
| Label expansion | US (FDA) | PROPECIA | — | 2002-04-10 | fda.gov ↗ |
| Approved | US (FDA) | PROSCAR | — | 1992-06-19 | fda.gov ↗ |
Trials 46
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials · 2 met primary | ||||||
| Phase 1 | NCT07322991 | Oct → Dec 2025 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07038941 | Mar → Jun 2024 | androgenetic alopecia | Beijing Dayspring Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02824380 | Jul → Oct 2016 | androgenetic alopecia | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02791243 | May → Jun 2016 | androgenetic alopecia | Polichem S.A. | Completed | No outcome recorded |
| Phase 1 | NCT01052870 | Dec 2008 → Dec 2009 | androgenetic alopecia | HairDx, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00663793 | Oct 2008 → May 2009 | hypogonadism | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT00870480 | Nov 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00871247 | Nov 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00650377 | Oct 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648791 | Sep → Oct 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00835666 | Jun 2002 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00835796 | Jun → Jul 2002 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01643629 | Jan → Oct 2012 | androgenetic alopecia | Kasiak Research Pvt. Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01227993 | Oct 2010 → Dec 2012 | retinal disorder | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00837252 | Feb 2009 → Apr 2010 | retinal disorder | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 214 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT06944145 | Dec 2025 → Jun 2029 expected | benign prostatic hyperplasia | Beth Israel Deaconess Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07076706 | Dec 2024 → Aug 2025 | baldness, male pattern | Beijing Dayspring Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02248701 | Apr 2017 → Aug 2021 | hypogonadism, male reproductive system disorder, spinal cord injury | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02213107 | Sep 2014 → Oct 2023 | prostate cancer | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT02055170 | Jun 2014 → Mar 2018 | non-small cell lung carcinoma | CancerCare Manitoba | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02146937 | Mar 2014 → Mar 2015 | prostatic adenoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01923090 | Aug 2012 → Oct 2013 | — | University of Birmingham | Unknown | No outcome recorded |
| Phase 2 | NCT01585441 | Apr 2012 → Dec 2013 | retinal disorder | National Eye Institute (NEI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00842751 | Jul → Nov 2009 | — | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00736645 | Aug 2008 → Dec 2012 | prostate cancer | Roswell Park Cancer Institute | Completed | Missed primary |
| Phase 2 | NCT00600691 | Mar 2008 → Dec 2011 | male reproductive system disorder | University of British Columbia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00438464 | Feb 2007 → Apr 2012 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00475501 | Jan 2007 → Mar 2012 | benign prostatic hyperplasia, hypogonadism, male, muscular atrophy | VA Office of Research and Development | Completed | Met primary |
| Phase 2 | NCT00003323 | May 1998 → May 2002 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05990400 | May → Oct 2023 | androgenetic alopecia | Indonesia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06601205 | Jan 2004 → Mar 2008 | prostate cancer, prostate intraepithelial neoplasia | Ente Ospedaliero Ospedali Galliera | Completed | No outcome recorded |
| Phase 36 trials · 2 met primary | ||||||
| Phase 3 | NCT07435012 | Apr 2026 → Dec 2027 expected | androgenetic alopecia | Triple Hair Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT05135468 | Dec 2021 → Mar 2023 | androgenetic alopecia | Cutia Therapeutics (Wuxi) Co., Ltd | Completed | Met primary |
| Phase 3 | NCT01534351 | Aug → Nov 2013 | benign prostatic hyperplasia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00127179 | Jan 2004 → Jul 2005 | benign prostatic hyperplasia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00396175 | Mar 1998 → Jan 2000 | androgenetic alopecia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00021814 | Dec 1995 → Nov 2001 | benign prostatic hyperplasia | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Met primary |
| Phase 45 trials · 1 missed | ||||||
| Phase 4 | NCT06001619 | Dec 2022 → Oct 2024 overdue | benign prostatic hyperplasia, prostate cancer | Turku University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02703220 | Jul 2015 → Jul 2026 overdue | sleep apnea syndrome | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 4 | NCT01296672 | Feb 2011 → Nov 2016 | prostate cancer | The University of Texas Health Science Center at San Antonio | Completed | Missed primary |
| Phase 4 | NCT00130767 | Dec 2004 → ? | benign prostatic hyperplasia | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Phase 4 | NCT07715448 | ? → Jan 2026 | benign prostatic hyperplasia, erectile dysfunction | Beni-Suef University | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04288427 | Sep 2020 → Jun 2026 overdue | benign prostatic hyperplasia, urinary tract obstruction | Beth Israel Deaconess Medical Center | Recruiting | No outcome recorded |
| — | NCT01342367 | Dec 2010 → May 2020 overdue | prostate cancer | University of Chicago | Active not recruiting | No outcome recorded |
| — | NCT01174953 | Jul 2010 → Mar 2013 | prostate cancer | University of Kansas | Completed | No outcome recorded |
| — | NCT00564252 | Feb → Oct 2006 | — | Iran University of Medical Sciences | Completed | No outcome recorded |
| Comparator or background therapy21 trials | ||||||
| Phase 0 | NCT04848181 Comparator | Jul 2019 → Jul 2020 | benign prostatic hyperplasia | Benha University | Completed | No outcome recorded |
| Phase 1 | NCT05611593 Comparator | Oct 2022 → Dec 2024 | androgenetic alopecia | Follicle Pharma Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT01829893 Comparator | Jan → Feb 2012 | benign prostatic hyperplasia | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04945226 Comparator | Sep 2021 → Feb 2022 | androgenetic alopecia | Inventage Lab., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06826001 Comparator | Feb → Jul 2025 overdue | androgenetic alopecia | Sheikh Zayed Medical College | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02781311 Comparator | Jul 2016 → Mar 2018 | alopecia | Allergan | Completed | Missed primary |
| Phase 2 | NCT02502669 Comparator | Jul 2015 → Jun 2017 | acne | Elorac, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00759135 Comparator | May 2007 → Jan 2008 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04594018 Comparator | Feb 2023 → May 2026 overdue | androgenetic alopecia | EMS | Recruiting | No outcome recorded |
| Phase 3 | NCT05023824 Comparator | Dec 2020 → Dec 2023 | benign prostatic hyperplasia | Gangnam Severance Hospital | Unknown | Met primary |
| Phase 3 | NCT03004469 Comparator | Aug 2016 → Mar 2018 | androgenetic alopecia | Polichem S.A. | Completed | Met primary |
| Phase 3 | NCT02548117 Comparator | Feb 2016 | polycythemia | Baylor College of Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01391156 Comparator | Mar 2011 → Mar 2012 | androgenetic alopecia | Mae Fah Luang University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01231607 Comparator | Oct 2010 → Feb 2012 | androgenetic alopecia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01139762 Background | Sep 2010 → Feb 2012 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT00542243 Comparator | Feb 2008 → Dec 2012 | benign prostatic hyperplasia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00564460 Comparator | Feb 2008 → Feb 2011 | benign prostatic hyperplasia | University of Alberta | Withdrawn | No outcome recorded |
| Phase 3 | NCT00064649 Comparator | Apr 2004 → Jun 2006 | benign prostatic hyperplasia | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02483195 Comparator | Aug 2016 → Aug 2018 | androgenetic alopecia | University of Florida | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01736033 Comparator | Feb 2012 → Feb 2017 | benign prostatic hyperplasia | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02244229 Comparator | Apr 1998 → Nov 2000 | benign prostatic hyperplasia | Boehringer Ingelheim | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 22
| Date | Issuer | Release |
|---|---|---|
| 2026-09-20 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT -
CU-40102 (TOPICAL FINASTERIDE SPRAY) OBTAINED
MARKETING APPROVAL BY THE MACAO PHARMACEUTICAL
ADMINISTRATION BUREAU cutiatx.com ↗
CU-40102 (TOPICAL FINASTERIDE SPRAY) OBTAINED MARKETING APPROVAL BY THE MACAO PHARMACEUTICAL ADMINISTRATION BUREAU |
| 2026-09-20 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory 自愿公告 - CU-40102（外用非那雄胺喷雾剂）获得澳门药物监督管理局上市批准 cutiatx.com ↗ |
| 2025-11-18 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - ABBREVIATED NEW DRUG APPLICATION FOR CU-40105 (SELF-DEVELOPED TOPICAL FINASTERIDE SPRAY) ACCEPTED BY THE NMPA cutiatx.com ↗ |
| 2025-08-01 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - CU-40102 (TOPICAL FINASTERIDE SPRAY) OBTAINED
MARKETING APPROVAL BY THE HONG KONG DEPARTMENT OF HEALTH cutiatx.com ↗
CU-40102 (TOPICAL FINASTERIDE SPRAY) OBTAINED MARKETING APPROVAL BY THE HONG KONG DEPARTMENT OF HEALTH |
| 2025-08-01 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory 自愿公告 - CU-40102（外用非那雄胺喷雾剂）获得香港卫生署上市批准 cutiatx.com ↗ |
| 2025-06-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - CU-40102 (TOPICAL FINASTERIDE SPRAY) OBTAINED MARKETING APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that CU-40102 (topical finasteride spray) of the Group has obtained marketing approval by the National Medical Products Administration (the “NMPA ”) of the People ’s Republic of China (the “PRC ” or “China ”). |
| 2024-11-28 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT -
RESULTS OF PHASE III CLINICAL TRIAL OF
CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-30101
(LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM)
IN CHINA WERE PRESENTED AT THE 19TH CDA ANNUAL MEETING cutiatx.com ↗
RESULTS OF PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA WERE PRESENTED AT THE 19TH CDA ANNUAL MEETING |
| 2024-11-28 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自願公告 - CU-40102（外用非那雄胺噴霧劑）及CU-30101（局部外用利多卡因丁卡因乳膏劑）中國III期臨床試驗結果在第十九屆CDA年會發佈 cutiatx.com ↗ |
| 2024-08-29 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自願公告 - CU-40102（外用非那雄胺噴霧劑）中國III期臨床試驗結果獲中華醫學會第八屆毛髮學術會議接受以電子壁報形式展示 cutiatx.com ↗ |
| 2024-04-29 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION
FOR CU-40102 (TOPICAL FINASTERIDE SPRAY)
IN HONG KONG, PRC cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that the New Drug Application (the “NDA”) for CU-40102 (topical finasteride spray) of the Group was submitted to the Department of Health of the Government of the Hong Kong Special Administrative Region (“Hong Kong ”) of the People ’s Republic of China (the “PRC”). |
| 2024-01-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-40102
(TOPICAL FINASTERIDE SPRAY)
ACCEPTED BY THE NATIONAL
MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that the New Drug Application (the “NDA”) for CU-40102 (topical finasteride spray) was accepted by the National Medical Products Administration (the “NMPA”) of the PRC. |
| 2024-01-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory 自愿公告 - CU-40102（外用非那雄胺喷雾剂）新药上市申请获得国家药品监督管理局受理 cutiatx.com ↗ |
| 2023-12-11 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIALS OF
CU-40102 (TOPICAL FINASTERIDE SPRAY) AND
CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC
PUBLISHED AT THE 18TH CDA ANNUAL MEETING cutiatx.com ↗
RESULTS OF PHASE III CLINICAL TRIALS OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED AT THE 18TH CDA ANNUAL MEETING |
| 2023-12-11 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自願公告 - CU-40102（外用非那雄胺噴霧劑）及 CU-10201（外用4%米諾環素泡沫劑） 中國III期臨床試驗結果在第十八屆CDA年會發佈 cutiatx.com ↗ |
| 2023-09-07 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - REGISTRATIONAL PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) REACHED PRIMARY ENDPOINT cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that the registrational Phase III clinical trial of the Group ’s CU-40102 (topical finasteride spray) conducted in China for the treatment of androgenetic alopecia reached primary endpoint. |
| 2023-09-07 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自愿公告 - CU-40102（外用非那雄胺喷雾剂）中国III期注册性临床试验达到主要终点 cutiatx.com ↗ |
| 2021-02-23 | Veru Inc. | Regulatory Veru Submits New Drug Application for Proprietary TADFIN for BPH verupharma.com ↗
today announced that it has submitted a 505(b)(2) New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for TADFIN ™ (tadalafil 5mg and finasteride 5mg) capsules, a novel oral daily dosing combination formulation, for the treatment of benign prostatic hyperplasia (BPH). |
| 2019-10-17 | Inventage Lab., Inc. | Results 피나스테라이드 1개월 지속형 주사제의 남성형 탈모 치료 효과 가능성 inventagelab.com ↗
인벤티지랩은 본 논문에서 현재 개발 중인 피나스테라이드 1개월 지속형 주사제의 효능 평가를 통해 남성형 탈모 치료 효과가 오리지널약인 ‘프로페시아’와 동일하거나 더 우수하다는 것을 입증하였으며, 또한 매일 복용해야 하는 경구제형을 1달 1회 주사제로 변경이 가능함에 대한 가능성을 확인하였다. |
| 2019-01-14 | Veru Inc. | Results Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia verupharma.com ↗
the clinical trial of the Company’s proprietary Tadalafil and Finasteride Combination tablet met the U.S. Food and Drug Administration’s (FDA) requirements for bioavailability and bioequivalence |
| 2013-03-18 | Eli Lilly and Company | Results New Study of Cialis® (tadalafil) Tablets Co-administered with Finasteride Meets Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia lilly.com ↗
On a pre-specified secondary measure, Cialis/finasteride also improved erectile function scores versus placebo/finasteride in those men who had both LUTS/BPH and erectile dysfunction (ED) at baseline. |
| 2006-06-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Receives First FDA Approval for Generic Proscar® Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Merck's Proscar® (Finasteride) Tablets, 5 mg. |
| 2004-10-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval Of Finasteride Tablets Usp, 5 Mg tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Finasteride Tablets USP, 5 mg. |
All press releases naming this drug 28 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 70 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Finasteride | “A 5-alpha reductase inhibitor (finasteride 5 mg or dutasteride 0.5 mg according to routine clinical practice) administered either once daily or every other day according to the...” NCT07715448 ↗66“A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male...” NCT05135468 ↗ “TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%).” NCT07435012 ↗ “The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.” NCT06001619 ↗ “Subjects were treated with a combination of finasteride and an alpha-blocker” PMID 18542722 ↗ Feb 2008 “finasteride 0.5mg twice daily, orally for 7 days” NCT00842751 ↗ “commercially available Finasteride 1mg Propecia” NCT05611593 ↗ “combination of minoxidil and finasteride” NCT07038941 ↗ “5% minoxidil / high dose of finasteride” NCT02824380 ↗ “2 % Minoxidil and /or Finasteride” NCT01643629 ↗ |
| Known as | Aindeem | ChEMBL registry synonym — accepted as the source's own label CHEMBL710 ↗ |
| Known as | CU-40102 | “A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male...” NCT05135468 ↗ |
| Known as | FIN | “INTRODUCTION: Tadalafil (TAD) 5 mg coadministered with finasteride (FIN) 5 mg significantly improves lower urinary tract symptoms (LUTS) in men with benign prostatic...” PMID 25353053 ↗ Oct 2014 |
| Known as | Finasterida | ChEMBL registry synonym — accepted as the source's own label CHEMBL710 ↗ |
| Known as | Finasteride component of entadfi | ChEMBL registry synonym — accepted as the source's own label CHEMBL710 ↗ |
| Known as | IY001 | “Drug: IY001(Finasteride)” NCT07322991 ↗ |
| Known as | MK-906 | ChEMBL registry synonym — accepted as the source's own label CHEMBL710 ↗ |
| Known as | MK0906 | “MK0906, finasteride / Duration of Treatment : 48 Weeks” NCT00396175 ↗ |
| Known as | NSC-741485 | ChEMBL registry synonym — accepted as the source's own label CHEMBL710 ↗ |
| Known as | NSC-759318 | ChEMBL registry synonym — accepted as the source's own label CHEMBL710 ↗ |
| Known as | Propecia | “Whether this recommendation should apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown.” PMID 17196507 ↗ Jan 20071“commercially available Finasteride 1mg Propecia” NCT05611593 ↗ |
| Known as | Proscar | “BACKGROUND: Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA).” PMID 17196507 ↗ Jan 20074“bioequivalence of Mylan's finasteride 5 mg tablets to Merck's Proscar® 5 mg tablets” NCT00648791 ↗ “oral drugs finasteride (Proscar) and doxazosin (Cardura), alone or together” NCT00021814 ↗ “Proscar® Tablets 5 mg” NCT00650377 ↗ “proscar” NCT02248701 ↗ |
| Known as | Prostide | ChEMBL registry synonym — accepted as the source's own label CHEMBL710 ↗ |
| Action | Inhibit | “Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.” NCT00003323 ↗ |
| Modality | Small molecule | — CHEMBL710 ↗ |
| Route | Oral | “The study will test whether the oral drugs finasteride (Proscar) and doxazosin (Cardura), alone or together” NCT00021814 ↗ |
| Target | SRD5A2 | “is an inhibitor of SRD5A2” NCT04288427 ↗ |